Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Aug 08, 2021 11:30am
138 Views
Post# 33669437

RE:RE:A Significant Loss Will be Recorded for Q2

RE:RE:A Significant Loss Will be Recorded for Q2
gudisgood wrote:
Also:

"Yes. So, first of all on the first question on Atea, this was an investment made by one of our fund. It was not a direct investment made by Knight and even though we are saying like there will be a reversal of gains, we’ve just decline that as you mentioned. We were still sitting on overall profit based on the cost base of where the financial into that company. So that fund really invested in the company pre-IPO."


Exactly - so shareholders really need to know what they are seeing in the numbers.
Same goes for the effects of amortization and depreciation on the bottom line.
Not as simple as just profit/loss ... but ... it's in the details.

Operations (specifically) is where we're looking for growth and efficiency (IMO).
<< Previous
Bullboard Posts
Next >>